Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coeptis Therapeutics Holdings (COEP) Accumulated Expenses (2021 - 2025)

Coeptis Therapeutics Holdings (COEP) has 5 years of Accumulated Expenses data on record, last reported at $210892.0 in Q3 2025.

  • For Q3 2025, Accumulated Expenses fell 71.59% year-over-year to $210892.0; the TTM value through Sep 2025 reached $210892.0, down 71.59%, while the annual FY2024 figure was $736884.0, 32.55% up from the prior year.
  • Accumulated Expenses reached $210892.0 in Q3 2025 per COEP's latest filing, down from $416209.0 in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $771035.0 in Q2 2024 and bottomed at $181998.0 in Q4 2022.
  • Average Accumulated Expenses over 5 years is $494151.7, with a median of $555950.0 recorded in 2023.
  • Peak YoY movement for Accumulated Expenses: skyrocketed 205.47% in 2023, then plummeted 71.59% in 2025.
  • A 5-year view of Accumulated Expenses shows it stood at $199126.0 in 2021, then fell by 8.6% to $181998.0 in 2022, then surged by 205.47% to $555950.0 in 2023, then skyrocketed by 32.55% to $736884.0 in 2024, then tumbled by 71.38% to $210892.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Accumulated Expenses were $210892.0 in Q3 2025, $416209.0 in Q2 2025, and $602447.0 in Q1 2025.